Concepedia

Bin Wu

BW

Statistics

Publications

37

Citations

6.8K

H-Index

27

Active since

2014

Affiliations

Agios Pharmaceuticals (United States)(Current)

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Dana-Farber Cancer Institute

Bin Wu is an author at Agios Pharmaceuticals (United States) specializing in medicine, pharmacology, and oncology.

ORCID

Publications per year

2014–2021

37

Publications

37

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

, , +13

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle et al. · The Lancet Oncology · 2020 · 1.1K citations · Full text

, , +8

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation

Andrew X. Zhu, Teresa Macarulla, Milind Javle et al. · JAMA Oncology · 2021 · 473 citations · Full text

, , +10

Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer

Xuechun Li, Zhao Sun, Gongxin Peng et al. · Theranostics · 2021 · 383 citations · Full text

, , +17

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein et al. · Blood · 2019 · 375 citations · Full text

, , +12

1–5 of 37